Introduction
Vascular endothelial growth factor (VEGF)-induced signalling cascades are essential for the highly proliferative blood vessel growth associated with vascularization of embryonic tissues. Homozygous knock-outs of growth factor (VEGF) or either of its two endothelial cell receptors, VEGFR-1 (fms-like tyrosine kinase,¯t-1), or VEGFR-2 (mouse foetal liver kinase-1, Flk-1, or human kinase insert domain-containing receptor, KDR) are embryonic lethal, as a result of abnormal endothelial cell development and vascular connections (Fong et al., 1995; Shalaby et al., 1995) . The critical dependence of vascular development on VEGF is emphasized by VEGF heterozygotes, in which the loss of only one VEGF allele is embryonic lethal (Carmeliet et al., 1996) . Angiogenesis in the adult is tightly regulated, occurring at regular intervals throughout the female reproductive cycle and also during the wound healing process. Persistent, unregulated angiogenesis has been linked to several pathological conditions, including diabetic retinopathy, rheumatoid arthritis, and the growth and metastasis of solid tumours (Folkman, 1995) . Anti-VEGF therapy is showing potential for use in the treatment of tumours. Several studies have shown that by blocking various components of the VEGF signalling system, tumour growth in mouse xenograft models can be inhibited (Millauer et al., 1994; Kim et al., 1993) . In contrast, the pro-angiogenic properties of VEGF are proving valuable for treatment of ischaemic heart and peripheral vascular diseases (Schratzberger et al., 2000) . In accordance with its role in vascular development, in vivo models of angiogenesis have shown VEGF to be a potent angiogenic growth factor (Leung et al., 1989) . In tissue culture systems, VEGF acts as an endothelial cell-speci®c mitogen, a vascular permeability factor, a cell survival factor and a chemoattractant for endothelial cells and monocytes (Ferrara and Davis-Smyth, 1997) . Despite much progress in recent years however, the molecular basis of these responses remains incompletely de®ned, partly as a consequence of cell type speci®c observations. Stimulation of endothelial cells with VEGF has been shown to induce the phosphorylation of many well known signalling components including PLCg, PI3K, RasGAP, Shc, Nck and SHPs-1 and -2 (Seetharam et al., 1995; Guo et al., 1995; Kroll and Waltenberger, 1997) . In addition, various protein components of intercellular junctions and focal adhesions (for example VE-cadherin, FAK and paxillin) , are phosphorylated in response to VEGF (Abedi and Zachary, 1997; Esser et al., 1998) . Phosphorylation of junctional proteins is thought to regulate both permeability and migration of endothelial cells. Cell growth and division, in the case of most growth factor receptor tyrosine kinases, are controlled by the MAPK pathway. Accordingly, VEGF has been shown to induce a strong activation of MAPK in primary endothelial cells (Yu and Sato, 1999; D'Angelo et al., 1995) .
Many studies have attempted to assign individual VEGF-induced responses to a particular receptor, either by expressing single receptors in cell types lacking endogenous receptors (Waltenberger et al., 1994; Takahashi and Shibuya, 1997) , by stimulating with receptor-speci®c ligands (Keyt et al., 1996; Meyer et al., 1999) , or by speci®cally ablating expression of one of the receptors with antisense oligonucleotides (Bernatchez et al., 1999) . Such studies have attributed VEGF-induced proliferation, migration and survival to activation of VEGFR-2, although this may be a consequence of the relatively weak growth factor-induced autophosphorylation of VEGFR-1 in mammalian cells (Waltenberger et al., 1994) . In this paper, we take a novel approach to study molecular responses mediated by activation of the individual VEGFRs. Through the use of chimeric receptors, in which the dimerization domain of the B subunit of DNA gyrase (Gyr B) is fused to the cytoplasmic domains of VEGFRs -1 and -2, we show that not only VEGFR-2, but also VEGFR-1, can be induced to autophosphorylate in endothelial cells by the addition of the dimerizing agent, coumermycin. We also show that once activated, both receptors have the intrinsic ability to activate downstream signalling cascades, as exempli®ed here by the activation of MAPK, Akt and PLCg. These results suggest that the inability of VEGFR-1 to mediate VEGF-induced signalling cascades in cell culture models may be a consequence of suboptimal activation of the receptor. Furthermore, we show that the phosphorylation of PLCg mediated by chimeric VEGFR-2, is dependent upon the Y1175 residue of this receptor.
Results

Activation of GyrB-VEGFR chimeras by coumermycin in porcine aortic endothelial cells
In order to establish a system whereby VEGFR-1 and -2 could be selectively activated in an endothelial cell background, plasmids were constructed encoding the cytoplasmic domains of VEGFR-1 and -2, individually fused to the N-terminal 24 kDa subdomain of Gyr B (Gilbert and Maxwell, 1994) . The myristoylation sequence of c-src was incorporated at the N-terminus of the chimeras to direct their localization to the inside of the cell membrane (Pellman et al., 1985) . To facilitate immunoprecipitation of the VEGFR-1 chimera, a myc-tag was introduced at a unique P¯M1 site in the juxtamembrane region. Constructs were introduced into porcine aortic endothelial (PAE) cells, and the expression of the chimeras in stable cell lines was assessed by immunoblotting ( Figure 1a) .
The potential of the system for use in analysing VEGFR-mediated signalling cascades was dependent on the ability of the small-molecule dimerizing agent, coumermycin, to regulate the activity of the chimeric receptors. Following coumermycin treatment, chimeric receptors were immunoprecipitated from their respective cell lines and the samples subjected to Western blot analysis with anti-phosphotyrosine antibodies. Coumermycin induced phosphorylation of chimeric VEGFR-1 and -2 in both a concentration-dependent ( Figure 1b ) and time-dependent (Figure 1c ) manner. Coumermycin had no eect on phosphorylation of fulllength`wild-type' VEGFR-1 and VEGFR-2 expressed in PAE or human embryonic kidney (HEK) 293 cells, indicating that it speci®cally activated the chimeric receptors through binding the GyrB domain (data not shown). At higher concentrations (41 mM), coumermycin inhibited phosphorylation of the GyrB-VEGFR chimeras, suggesting that at these doses the drug is saturating the expressed receptors, thereby inhibiting their dimerization and activation. To con®rm that the mechanism of coumermycin-induced receptor activation required dimerization, experiments were repeated using Novobiocin, an antibiotic related in structure to coumermycin, but which binds GyrB in a 1 : 1 ratio (Farrar et al., 1996) . Over the same concentration range, Novobiocin was unable to promote receptor activation (data not shown). Maximal activation of chimeric VEGFR-2 in response to coumermycin peaked between 5 and 15 min in repeated experiments. Phosphorylation of chimeric VEGFR-1 was somewhat more sustained than that of VEGFR-2, still being observed more than 90 min after coumermycin-stimulation (Figure 1c ). This could re¯ect a dierence in sensitivity to tyrosine phosphatases, such as HCPTPA, recently described as a speci®c phosphatase for VEGFR-2 (Huang et al., 1999) . Since VEGFR-1 is believed to have a very weak intrinsic kinase activity, we wished to verify that the phosphorylation induced by coumermycin was dependent on the receptor's intrinsic catalytic activity. We therefore analysed the eect of coumermycin on PAE cells expressing a kinase-inactive VEGFR-1 chimera, containing a lysine to alanine mutation at the ATP-binding site (K861A). As shown in Figure 1d , coumermycin failed to induce phosphorylation of this chimera, thereby con®rming that VEGFR-1 was autophosphorylating in response to coumermycin.
Both VEGFR-1 and VEGFR-2 can activate the MAP kinase pathway in endothelial cells
Having developed a system in which VEGFR-1 and -2 could be induced to phosphorylate in endothelial cells, we were then able to study molecular responses induced by activation of the individual receptors. The MAPK pathway has a central role in controlling signals for growth from most growth factor receptor tyrosine kinases. VEGF has been consistently shown to induce both MAPK activation and cell proliferation in primary endothelial cells (Yu and Sato, 1999; D' Angelo et al., 1995) , as well as in VEGFR-2-, but not VEGFR-1-transfected PAE cells (Waltenberger et al., 1994) . To determine whether this selectivity was a consequence of suboptimal VEGFR-1 activation or was indeed a speci®c characteristic of VEGFR-2, we analysed ERK activation downstream of activated chimeras using antibodies which speci®cally detect the phosphorylated, active forms of ERK 1 and 2. As shown in Figure 2 , ERK activation was mediated through both VEGFR-1 and -2, in a concentration-( Figure 2a ) and time- (Figure 2b ) dependent manner. Essentially no dierence was observed in the extent, or duration of activation induced by VEGFR-1 and -2.
VEGFR-1 and -2 stimulate phosphorylation of PLC g and Akt
Two other pathways reported to be activated downstream of VEGF in endothelial cells are those of PLC g (Guo et al., 1995; Mukhopadhyay et al., 1998) and PI3K/Akt (Thakker et al., 1999; Gerber et al., 1998) . Interactions of PLC g with both VEGFR-1 and -2 have been observed in yeast two-hybrid assays (Cunningham et al., 1997; Wu et al., 2000a) . In mammalian cells, VEGF-induced PLC g phosphorylation has been observed in primary endothelial cells and VEGFRexpressing 3T3 ®broblasts. However, reported interactions are limited to those between PLCg and VEGFR-2, both in 3T3/VEGFR-2 cells , and via the adaptor protein VRAP, in HUVECs (Wu et al., 2000b) . Using the chimeric receptor system described here, activation of GyrB ± VEGFR-2, and to a lesser extent GyrB ± VEGFR-1, led to an increase in phosphorylation of PLCg, indicating that both receptors have the potential to stimulate this pathway in endothelial cells (Figure 3a) .
The PI3K/Akt pathway is used by many growth factors, including VEGF, to promote cell survival. Many receptor tyrosine kinases couple to this pathway via the recruitment, and subsequent phosphorylation, of the p85 subunit of PI3K. This subunit has been shown to bind VEGFR-1, although not VEGFR-2, in yeast two-hybrid assays (Cunningham et al., 1995) . In addition, VEGF-induced phosphorylation of p85 has been reported in BAECs, although observations in HUVECs have been con¯icting (Guo et al., 1995; Abedi and Zachary, 1997; Thakker et al., 1999) . Expression of the individual receptors in PAE cells has failed to demonstrate any interactions between the receptors and p85, although both constitutive complex formation between VEGFR-2 and p85 (Thakker et al., 1999) , and their indirect association, via the adaptor protein VRAP, has been reported in HUVECs (Wu et al., 2000b) . Whatever the mechanism by which PI3K couples to VEGF signalling, its activation is required for VEGF-induced Akt activation (Gerber et al., 1998) . Through the use of receptor-selective VEGF mutants, this response has been attributed to VEGFR-2 (Gerber et al., 1998) . We investigated the abilities of the individual chimeric receptors to mediate this pathway by analysing whole cell lysates for phosphorylation of Akt with phosphospeci®c antibodies. As shown in Figure 3b , Akt activation was mediated through both VEGFR-1 and -2. expressing GyrB-VEGFR-1 (PAE/GYR.R1), or GyrB ± VEGFR-2 (PAE/GYR.R2) were analysed by immunoblotting with antibodies recognizing the cytoplasmic domains of VEGFR-1 and VEGFR-2. For comparison, lysates from untransfected PAE cells were analysed (PAE). (b) Cells were incubated for 15 min, at 378C, with increasing concentrations of coumermycin (Cou). GyrB ± VEGFR-1 and GyrB ± VEGFR-2 chimeras were immunoprecipitated from cell lysates with anti-myc and anti-VEGFR-2 antibodies respectively, and subjected to SDS ± PAGE and immunoblotting with antibodies recognizing phosphotyrosine (a-PY). Blots were stripped and re-probed with antibodies recognizing the corresponding VEGF receptor (a VEGFR-1, a VEGFR-2). Results are representative of experiments performed on two independent clones. (c) Cells were treated with 100 nM Coumermycin (Cou) for increasing time intervals, and chimeric receptors were immunoprecipitated and analysed as described above. (d) PAE cells expressing an ATP-binding site mutant of VEGFR-1 (PAE/GYR.R1(K861A)) were analysed for expression of the mutant chimera as for (a) and a clone expressing similar levels of chimera to the wild-type, was selected. PAE/GYR.R1 (K861A) cells were stimulated for 15 min with 100 nM coumermycin, and immunoprecipitates analysed for the presence of phophotyrosine as described for (b). For comparison, lysates from PAE/GYR.R1 cells were analysed in parallel Y1175 of VEGFR-2 is required for activation of PLCg, but not of ERK nor Akt
Having demonstrated that VEGFR chimeras could activate signalling pathways representative of those activated by endogenous receptors in primary endothelial cells, we wished to determine whether activation of any of these pathways (MAP kinase, Akt, PLCg) could be correlated with phosphorylation of a speci®c site on the VEGFR. These studies would not only extend our knowledge of important interaction sites for signalling components in vivo, an area which is currently lacking in the literature, but would also suggest that the chimeric receptors couple to signalling pathways in the same way as the endogenous receptors, i.e. by acting as docking sites for selected SH2-and PTB-domain containing proteins, and are not simply phosphorylating proteins promiscuously. For these studies we chose to analyse the Y1175 residue of VEGFR-2 since this site has previously been shown to bind PLCg, and the Shc-like protein Sck, in yeast (Warner et al., 2000; Cunningham et al., 1997; Igarashi et al., 1998) , suggesting that this site may be required for activation of PLCg, or the ERK pathway in vivo. Stable PAE cell lines expressing the point mutant of VEGFR-2 (Y1175F) were generated. Western blot analysis con®rmed that the expression levels of the mutant and wild-type chimeras were similar (data not shown). Maximal phosphorylation of the Y1175F mutant was induced over the same concentration range of coumermycin as the wild-type VEGFR-2 chimera (Figure 4a) , and occurred over the same time-course, peaking between 5 and 15 min of stimulation (data not shown). We then assessed whether mutation of Y1175 had any eect on ERK activation. As shown in Figure  4b , the Y1175F mutant chimeric receptor activated MAPK in a manner similar to the wild-type chimera. In contrast, mutation of the Y1175 residue completely abolished the ability of the VEGFR-2 chimera to induce Figure 2 Chimeric GyrB ± VEGFR-1 and -2 both activate the ERK pathway in PAE cells, (a) PAE cells expressing the GyrB-VEGFR-1 chimera (PAE/GYR.R1), or the GyrB-VEGFR-2 chimera (PAE/GYR.R2) were stimulated with increasing concentrations of coumermycin (Cou) for 15 min at 378C. For comparison PAE cells were treated similarly. Whole cell lysates from duplicate wells were analysed by immunoblotting with antibodies recognizing the phosphorylated form of ERK1 and ERK2 (pERK1/2). Western blots were stripped and re-probed with antibodies recognizing both phosphorylated and non-phosphorylated ERK1 and ERK2. (b) PAE/GYR.R1 and PAE/GYR.R2 cells were treated for increasing times with 100 nM coumermycin. Whole cell lysates were analysed for the presence of phosphorylated ERK1 and ERK2 (pERK1/2), or total ERK1 and ERK2, as described for (a)
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Figure 3 PLCg and Akt are activated by VEGFR-1 and VEGFR-2 chimeras. (a) PAE cells expressing the GyrB ± VEGFR-1 chimera (PAE/GYR.R1), or the GyrB ± VEGFR-2 chimera (PAE/GYR.R2) were stimulated with 1 mM coumermycin (Cou) for 15 min at 378C. PLCg was immunoprecipitated from cell lysates, and analysed by Western blotting for the presence of phosphotyrosine (PY). Immunoblots were stripped and re-probed with an anti-PLCg antibody to control for the amount of precipitated protein.
(b) Whole cell lysates from cells treated as described in (a) were analysed by immunoblotting with an antibody recognizing phosphorylated Akt (pAkt), or total Akt (Akt) as indicated phosphorylation of PLCg, indicating that Y1175 may be the primary site for recruiting PLCg in vivo (Figure 4c ). Activation of Akt by VEGFR-2 was not aected by mutation of the Y1175 residue (Figure 4d ).
Discussion
Attempts to characterize VEGF-induced signalling cascades in mammalian cells have so far been impaired by limited activation of VEGFR-1 in response to growth factors (Waltenberger et al., 1994) . Functional coupling of VEGFR-1 to cellular responses has only convincingly been demonstrated in monocytes (Barleon et al., 1996) . Studies in which receptors have been introduced into mammalian cells have been restricted to cell types which lack endogenous VEGFRs, and may consequently also lack important components of VEGF signalling cascades (Waltenberger et al., 1994; Takahashi and Shibuya, 1997) , for example the VEGFR-2 co-receptor, neuropilin-1 (Soker et al., 1998) . In an eort to produce autophosphorylationcompetent receptors which can be speci®cally activated over endogenous receptors, we constructed chimeric VEGFRs. Chimeras have been used to facilitate the study of signalling through orphan receptors. Most commonly this involves replacing the extracellular domain of the orphan receptor with that of a second receptor for which a functional growth factor has been characterized (Prigent and Gullick, 1994). Such studies Figure 4 Mutation of Y1175 inhibits PLCg activation by GyrB ± VEGFR-2 chimera, but has no eect on activation of ERK, or Akt. (a) PAE cells expressing wild-type GyrB ± VEGFR-2 chimera (PAE/GYR.R2), or a point mutant in which the tyrosine residue at position 1175 was changed to phenylalanine (PAE/GYR.R2 (Y1175F)), were treated with the indicated concentrations of coumermycin for 15 min. Chimeric receptors were precipitated from cell lysates with an antibody recognizing VEGFR-2 (a VEGFR-2), and analysed for the presence of phosphotyrosine by immunoblotting with an anti-phosphotyrosine antibody (a PY).
To control for the amount of protein precipitated, immunoblots were re-probed with an anti-VEGFR-2 antibody. (b) PAE/GYR.R2 cells and PAE/GYR.R2 (Y1175F) cells were stimulated for 15 min with the indicated concentrations of coumermycin, or with 1 mM coumermycin for the indicated times. Cell lysates were prepared and analysed for the presence of ERK1 and 2 (ERK1/2), and active ERK1 and ERK2 (pERK1/2) as described in Figure 2 . (c) PAE/GYR.R2 and PAE/GYR.R2 (Y1175F) cells were treated with coumermycin, and analysed for the presence of phosphorylated PLCg as described in Figure 3 . (d) PAE/GYR.R2 and PAE/ GYR.R2 (Y1175F) cells were treated with coumermycin, and analysed for the presence of phosphorylated Akt as described in Figure 3 may be complicated by activation of low levels of the endogenous receptor upon addition of growth factor. In addition, interactions may exist between the extracellular domain of the chimeric receptor and other cellular components, which would not normally in¯uence signalling through the orphan receptor. Alternatively, chimeras can be controlled by small, non-mammalian molecules, thereby enabling study in the most appropriate cell types without activation of endogenous receptors. Two such ligands are FK1012 and coumermycin A 1 , which dimerize FKBP12, an immunophilin, and the B subunit of bacterial DNA gyrase, Gyr B, respectively. Chimeras of Janus kinase-2, Raf-1, and receptors for insulin, PDGF and G-CSF, have all been successfully activated, via dimerization, upon addition of one of these two dimerizing agents (Farrar et al., 1996; Mohi et al., 1998; Kume et al., 1999; Yang et al., 1997) .
Here we have used GyrB ± VEGFR chimeras to demonstrate that VEGFR-1, as well as VEGFR-2 has a competent kinase activity, and can transduce signals in endothelial cells. This suggests that the apparent inability of VEGFR-1 to activate signalling pathways in endothelial cells is not due to a de®cient kinase, as is the case with certain atypical tyrosine kinases such as Ryk and c-erbB3 (Katso et al., 1999; Sierke et al., 1997) , but a result of inecient stimulation. Whether this resistance to activation is a physiological property of the receptor, or due to the requirement of as yet unidenti®ed components, such as additional growth factors or co-factors, remains open to question. It is possible that the presence of an inhibitor, such as a phosphatase, normally restricts the activity of the fulllength receptor. Such a control mechanism may have been overcome with the chimeric receptors described here. The ability of the VEGFR-1 chimera to autophosphorylate gives the chimeric system an important advantage over the full-length receptors when studying potential signalling cascades.
In contrast to VEGFR-1, the role of VEGFR-2 in promoting VEGF-induced proliferation, migration and permeability is much more clearly de®ned. Nevertheless, evidence linking activation of selective signalling pathways with phosphorylation of distinct sites on the receptor is largely lacking in vivo. Experiments in which point-mutants of full-length VEGFR-2 were expressed in HEK293 cells ruled out Y951 and Y996 as candidate sites for initiating PLCg activation in vivo and suggested the existence of additional autophosphorylation sites which had not yet been reported (Dougher and Terman, 1999) . Y1175 has been shown to bind both the adaptor Sck (ShcB) (Igarashi et al., 1998; Warner et al., 2000) , and PLCg in yeast (Cunningham et al., 1997) . This site corresponds to Y1169 of VEGFR-1, a residue which is phosphorylated when the receptor is expressed in insect cells, and associates with PLCg (Sawano et al., 1997) . The data presented here suggest that Y1175 is involved in the activation of PLCg, possibly by binding one, or other of its SH2 domains. In contrast, the Y1175 residue is dispensible for activation of both ERK and Akt. It is of note that our chimeric VEGFR-2 constructs lack the juxtamembrane Y801 of the full-length receptor, which has also been shown to bind to PLCg in the yeast twohybrid assay. Our results demonstrate that VEGFR-2 is able to mediate PLCg activation in the absence of the Y801 residue, but not in the absence of both Y801 and Y1175. Whether the Y1175 mutation alone is capable of ablating VEGFR-2-mediated PLCg activation, in the context of the full-length VEGFR-2, is currently under investigation. Interestingly, in sinusoidal endothelial cells, it has been suggested that PLCg has a major role in promoting activation of the MAP kinase pathway via production of diacylglycerol, and subsequent activation of PKC (Takahashi et al., 1999) . In our system this appears not to be the case, since elimination of PLCg activation had no obvious eect on ERK activity.
Our earlier observation that Sck, but not Shc, could bind to Y1175 of VEGFR-2 in transfected cells, led us to speculate that this site may be important for initiating the MAP kinase pathway, via the recruitment of Grb2/Sos to receptor-bound Sck (Warner et al., 2000) . Our current data suggests that if this mechanism exists, it is clearly not the only pathway for activation of ERK by VEGFR-2. Involvement of Sck in VEGFR-2 signalling may be limited to a sub-set of endothelial cells, or given its high expression in nervous tissue, may be a specialized component of signalling in Schwann cells which have recently been shown to express VEGFR-2, and have a migratory response to VEGF (Schratzberger et al., 2000) .
The mechanism by which VEGFR-2 recruits and activates PI3 kinase is unclear, since this receptor lacks the YXXM motif present in most receptor tyrosine kinases which eciently activate PI3 kinase by recruitment of the p85 subunit. Assuming that Akt activation is dependent upon PI3 kinase activity in our system, a point which may warrant further experimentation, we can conclude that the Y1175 phosphorylation site is not involved in binding p85, nor in recruiting other proteins responsible for activating PI3 kinase. Further mutational analysis might permit identi®cation of phosphotyrosine residues important for activation of the MAPK and PI3K/Akt pathways. It will clearly be of interest to determine whether the VEGFR-1 and -2 chimeras have equivalent abilities to promote endothelial cell dierentiation in tube morphogenic assays in a dierent endothelial cell model. Ultimately, the control provided by such a chimeric receptor system may have potential for incorporation into therapeutic strategies for ischaemic disease.
Materials and methods
Antibodies
Antibodies recognizing VEGFR-2 (sc-6251), VEGFR-1 (sc-316), the 9E10 Myc epitope (sc-40, AC), phosphotyrosine (sc-7020), MAPK (sc-94), Akt1/2 (sc-8312) and PLCg (sc-81) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies recognizing phospho-MAPK (9106S) and phospho-Akt (9271S) were purchased from New England BioLabs (Hitchin, Hertfordshire, UK). Horseradish peroxidase-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology and Jackson ImmunoResearch Laboratories (West Grove, PA, USA).
Generation of chimeric constructs
Complementary oligonucleotides (5'-AGCTTACCATGGG-GAGCAGCAAGAGCAAGCCCAAGGACCCCAGCCAG-CGC-3'; 5'-TCGAGCGCTGGCTGGGGTCCTTGGGCTT-GCTCTTGCTGCTCCCCATGGTA-3') encoding the myristoylation site of c-src (Pellman et al., 1985) were cloned as a HindIII ± XhoI fragment into the corresponding sites of pcDNA3/Neo (Invitrogen, Groningen, The Netherlands). A DNA fragment encoding the 24 kDa, N-terminal sub-domain of DNA GyrB (Gilbert and Maxwell, 1994) was ampli®ed from the full-length cDNA, kindly provided by Prof A Maxwell (University of Leicester, UK), by the polymerase chain reaction (PCR) with the primers (5'-ACAGCGATCTC-GAGTTCTTATGACTCCTCCAGTAT-3'; 5'-CGTAGGAT-CCCCTTCATAGTGGAAGTGGTC-3'). The resultant fragment was subcloned into the XhoI ± BamHI sites of pcDNA3-src to generate a fusion between the src and gyrase sequences. The cytoplasmic domain of VEGFR-2, lacking the juxtamembrane tyrosine residue, Y801 (Warner et al., 2000) , was subcloned into the BamHI ± XbaI sites of pcDNA3-src-gyr to generate a fusion between the gyrase and VEGFR-2 sequences. A Y1175F point mutation was introduced into the VEGFR-2 sequence of pcDNA3-src-gyr-VEGFR-2 using the Quik-Change site-directed mutagenesis kit (Stratagene, West Cedar Creek, TX, USA) and the primers 5'-GCAGGA-TGGCAAAGAATTCATTGTTCTTCCG-3'; 5'-CGGAAG-AACAATGAATTCTTTGCCATCCTG-3'. The cytoplasmic domain of VEGFR-1 was ampli®ed by PCR from pcDNA1/ Neo-Flt-1 (Waltenberger et al., 1994) with the primers 5'-CG-ATGGATCCCCGAAAAATGAAAAGGTCTTCTG-3'; 5'-GC ATTCTAGACTAGATGGGTGGGGTGGAGTACA-3'. The resultant fragment was subcloned into the BamHI ± XbaI sites of pcDNA3-src-gyr to generate a fusion between the gyrase and VEGFR-1 sequences. Complementary oligonucleotides (5'-GGAGCAGAAACTAATAAGCGAAGAAGA-CCTAGCCAA-3'; 5'-GCTAGGTCTTCTTCGCTTATTAG-TTTCTGCTCCTTG-3') encoding the 9E10 myc epitope tag were subcloned into the P¯MI site of VEGFR-1, to generate a myc-tagged src-gyr-VEGFR-1 fusion. A K861A point mutation was introduced into the VEGFR-1 sequence of pcDNA3-src-gyr-VEGFR-1, using site-directed mutagenesis and the primers 5'-GGACTGTGGCTGTGGCCATGCTGA-AAGAGGG-3'; 5'-CCCTCTTTCAGCATGGCCACAGCC-ACAGTCC-3', thereby generating a kinase-inactive version of myc-tagged src-gyr-VEGFR-1.
Establishment of PAE cell lines stably expressing chimeric receptors
Cell culture reagents were obtained from Gibco BRL Life Technologies (Life Technologies Ltd., Paisley, Scotland). PAE cells (Waltenberger et al., 1994) (kindly provided by Dr L Claesson-Welsh) were routinely cultured in Ham's F-12 medium supplemented with 10 mg/ml streptomycin, 1000 units/ml penicillin and 10% foetal calf serum. 24 h prior to transfection, cells were seeded at a density of 2.5610 5 cells per well of 6-well plate. Chimeric constructs were transfected using fugene reagent (Roche Diagnostics Ltd., East Sussex, UK), according to the manufacturer's protocol. Twenty-four hour post-transfection, cells were split into 10 cm petri dishes at varying dilutions, grown for a further 24 h, and then selected in 0.4 mg/ml G418 sulphate (Promega, Southampton, UK). Clones were picked after 2 weeks and, once established, cells were seeded at a density of 5610 4 cells per well of 24-well plate for analysis of receptor expression. Twenty-four hours later, cells were boiled in SDS-containing sample buer, subjected to SDS ± PAGE and transferred onto a nitrocellulose membrane (Hybond ECL; Amersham, UK). Proteins were detected by immunoblotting, using antibodies as described in individual ®gure legends and a chemiluminescence-based detection system (Renaissance; NEN Life Science, Boston, MA, USA).
Immunoprecipitations
Cells were seeded at a density of 7.2610 5 per 6 cm diameter petri dish. The following day, cells were incubated in serum free medium for 16 ± 24 h. Cells were stimulated with Coumermycin A 1 (Sigma-Aldrich Company Ltd., Dorset, UK), diluted from a stock solution (5 mM) prepared in DMSO, at 378C as described in individual ®gure legends. Following treatment, cells were washed twice with ice-cold PBS and lysed for 10 min at 48C in lysis buer (1% Triton X-100, 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 5 mM EGTA, 25 mM benzamidine, 100 mM Na 3 VO 4 , 100 mM NaF), containing a mammalian protease inhibitor cocktail (Sigma). Cell debris was removed by centrifugation at 25 000 g, 48C, for 5 min and protein precipitated from lysates overnight using 2 mg antibody pre-bound to 2.5 mg protein A-sepharose (for precipitations with anti-PLCg antibody) or protein G-sepharose (for precipitations with anti-VEGFR-2 antibody). For immunoprecipitation of myc-tagged VEGFR-1, protein was precipitated with 10 mg of the Myc antibody agarose conjugate. Immunoprecipitates were washed four times with TBS (50 mM Tris/HCl, pH 7.4, 150 mM NaCl)/ 0.1% Triton X-100. Receptor was eluted from beads by boiling in SDS-containing sample buer, subjected to SDS ± PAGE, transferred to nitrocellulose and analysed by Western blotting as described in individual ®gure legends.
Detection of activated ERK1/2 and Akt with phosphospecific antibodies
Cells were seeded at density of 5610 4 per well of 24-well plate. The following day, cells were incubated in serum free medium for 16 ± 24 h. Cells were stimulated with coumermycin A 1 at 378C as described in individual ®gure legends. Following treatment, cells were boiled in SDS-containing sample buer and analysed by SDS ± PAGE and immunoblotting as described in individual ®gure legends.
Abbreviations BAEC, bovine aortic endothelial cells; ERK, extracellular regulated kinase; GyrB, B subunit of DNA gyrase; HUVEC, human umbilical vein endothelial cells; PAE cells, porcine aortic endothelial cells; PI3 kinase, phosphatidyl inositol 3'-kinase; PLCg, phospholipase Cg; VEGF, vascular endothelial growth factor, VEGFR-1, VEGF receptor 1; VEGFR-2, VEGF receptor 2
